X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (1159) 1159
humans (1152) 1152
index medicus (666) 666
middle aged (580) 580
adult (527) 527
oncology (484) 484
obstetrics & gynecology (472) 472
ovarian cancer (457) 457
aged (401) 401
cancer (349) 349
fallopian-tube (323) 323
ovarian neoplasms - pathology (312) 312
fallopian tube neoplasms - pathology (217) 217
ovarian neoplasms - drug therapy (214) 214
ovarian neoplasms - surgery (213) 213
carcinoma (208) 208
surgery (207) 207
obstetrics and gynecology (206) 206
chemotherapy (190) 190
fallopian tubes - surgery (178) 178
women (158) 158
aged, 80 and over (154) 154
retrospective studies (154) 154
hematology, oncology and palliative medicine (149) 149
ovariectomy (140) 140
treatment outcome (138) 138
fallopian tube neoplasms - drug therapy (137) 137
neoplasm staging (135) 135
hysterectomy (134) 134
fallopian tube neoplasms - surgery (133) 133
ovarian neoplasms - genetics (132) 132
health aspects (131) 131
laparoscopy (127) 127
care and treatment (125) 125
diagnosis (124) 124
research (124) 124
fallopian tube (122) 122
pregnancy (122) 122
tumors (121) 121
peritoneal neoplasms - drug therapy (114) 114
analysis (108) 108
survival (108) 108
animals (106) 106
carcinoma, ovarian epithelial (104) 104
antineoplastic combined chemotherapy protocols - therapeutic use (103) 103
ca-125 antigen - blood (101) 101
mutation (99) 99
ovarian neoplasms - diagnosis (97) 97
medicine & public health (96) 96
diagnosis, differential (95) 95
disease-free survival (95) 95
risk factors (93) 93
prognosis (92) 92
fallopian tubes (90) 90
fallopian tubes - pathology (87) 87
adolescent (86) 86
fallopian tube neoplasms - diagnosis (83) 83
peritoneal neoplasms - pathology (82) 82
article (79) 79
ovarian-cancer (78) 78
pathology (78) 78
young adult (75) 75
paclitaxel (74) 74
ovarian neoplasms - blood (73) 73
genetic aspects (68) 68
risk (65) 65
ultrasonography (65) 65
follow-up studies (63) 63
gynecology (63) 63
ovarian neoplasms - metabolism (63) 63
immunohistochemistry (62) 62
bevacizumab (61) 61
breast-cancer (61) 61
neoplasms, glandular and epithelial - pathology (61) 61
gynecologic-oncology-group (60) 60
oncology, experimental (60) 60
antineoplastic agents - therapeutic use (59) 59
ovarian neoplasms - mortality (59) 59
ovary (59) 59
female genital diseases and pregnancy complications (58) 58
management (58) 58
metastasis (58) 58
ovarian neoplasms - prevention & control (58) 58
prevention (58) 58
primary peritoneal cancer (58) 58
salpingectomy (58) 58
breast cancer (57) 57
genes, brca1 (57) 57
peritoneal neoplasms - surgery (57) 57
reproductive biology (57) 57
survival rate (56) 56
clinical trials (55) 55
carboplatin (54) 54
carboplatin - administration & dosage (52) 52
genes, brca2 (52) 52
brca1 (51) 51
epithelial ovarian (51) 51
neoplasm recurrence, local - drug therapy (51) 51
fallopian tube neoplasms - blood (50) 50
genetic predisposition to disease (50) 50
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1244) 1244
Russian (9) 9
German (8) 8
French (7) 7
Italian (4) 4
Polish (4) 4
Chinese (3) 3
Czech (2) 2
Hebrew (2) 2
Japanese (2) 2
Bulgarian (1) 1
Danish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gynecologic Oncology, ISSN 0090-8258, 2014, Volume 134, Issue 3, pp. 455 - 461
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 09/2017, Volume 146, Issue 3, pp. 484 - 490
Indoleamine 2,3-dioxygenase-1 (IDO1) is a key regulator of immune tolerance in ovarian cancer. This study investigated efficacy and safety of the IDO1 enzyme... 
Epacadostat | IDO1 enzyme inhibitor | Tamoxifen | Ca-125 | Ovarian cancer | SURVIVAL | DIAGNOSIS | PROTEIN | PROGNOSIS | INDOLEAMINE 2,3-DIOXYGENASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | IMMUNOTHERAPY | EXPRESSION | T-CELLS | Recurrence | Neoplasms, Glandular and Epithelial - chemistry | Oximes - pharmacokinetics | Oximes - adverse effects | Peritoneal Neoplasms - blood | Humans | Middle Aged | Oximes - therapeutic use | Response Evaluation Criteria in Solid Tumors | Fatigue - chemically induced | Peritoneal Neoplasms - chemistry | Antineoplastic Agents, Hormonal - adverse effects | Early Termination of Clinical Trials | Fallopian Tube Neoplasms - blood | Neoplasms, Glandular and Epithelial - blood | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - chemistry | Exanthema - chemically induced | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Ovarian Neoplasms - drug therapy | Pruritus - chemically induced | Fallopian Tube Neoplasms - drug therapy | Drug Eruptions - etiology | Ovarian Neoplasms - chemistry | CA-125 Antigen - blood | Indoleamine-Pyrrole 2,3,-Dioxygenase - analysis | Ovarian Neoplasms - blood | Survival Rate | Sulfonamides - pharmacokinetics | Disease-Free Survival | Sulfonamides - therapeutic use | Tamoxifen - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Sulfonamides - adverse effects | Aged | Tamoxifen - adverse effects | Indoleamine-Pyrrole 2,3,-Dioxygenase - antagonists & inhibitors | Care and treatment | Chemotherapy | Enzyme inhibitors | Cancer | Medical research | Medicine, Experimental
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 13, pp. 1411 - 1420
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2015, Volume 139, Issue 2, pp. 221 - 227
Abstract Background Readmission within 30 days is a measure of care quality. Ovarian cancer patients are at high risk for readmission, but specific risk... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Chemotherapy | Readmissions | Ovarian cancer | 30-DAY HOSPITAL READMISSION | COLORECTAL SURGERY | PREDICTOR | SURGICAL CYTOREDUCTION | CANCER | CARE | OBSTETRICS & GYNECOLOGY | DISCHARGE | COST | ONCOLOGY | STAY | Multivariate Analysis | Peritoneal Neoplasms - blood | Humans | Middle Aged | Ovarian Neoplasms - pathology | Ovarian Neoplasms - complications | Cytoreduction Surgical Procedures | Peritoneal Neoplasms - complications | Neoplasm, Residual | Fallopian Tube Neoplasms - blood | Peritoneal Neoplasms - drug therapy | Carcinoma - complications | Time Factors | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Fallopian Tube Neoplasms - complications | Chemotherapy, Adjuvant | Carcinoma - pathology | Neoplasms, Cystic, Mucinous, and Serous - complications | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Body Mass Index | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Ascites - etiology | Carcinoma - blood | Neoplasms, Cystic, Mucinous, and Serous - pathology | Bevacizumab - administration & dosage | CA-125 Antigen - blood | Double-Blind Method | Obesity - complications | Risk Factors | Carboplatin - administration & dosage | Ovarian Neoplasms - blood | Fallopian Tube Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Cystic, Mucinous, and Serous - blood | Neoplasm Staging | Patient Readmission - statistics & numerical data | Medical research | Clinical trials | Medicine, Experimental | Risk factors | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2013, Volume 19, Issue 18, pp. 5227 - 5239
Purpose: The aim of this study was to identify and validate novel predictive and/or prognostic serum proteomic biomarkers in patients with epithelial ovarian... 
PHASE-III TRIAL | BREAST-CANCER | MESOTHELIN | ONCOLOGY-GROUP | THERAPY | ONCOLOGY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | PLUS BEVACIZUMAB | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Prognosis | Follow-Up Studies | Endometrial Neoplasms - mortality | Peritoneal Neoplasms - blood | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Adenocarcinoma, Clear Cell - blood | Cystadenocarcinoma, Serous - drug therapy | Bevacizumab | Patient Selection | Fallopian Tube Neoplasms - blood | Peritoneal Neoplasms - drug therapy | Adenocarcinoma, Mucinous - blood | Angiogenesis Inhibitors - therapeutic use | Chromatography, Liquid | Adult | Female | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Cystadenocarcinoma, Serous - blood | Antibodies, Monoclonal, Humanized - therapeutic use | Ovarian Neoplasms - blood | Survival Rate | Peritoneal Neoplasms - mortality | Biomarkers, Tumor - blood | Adenocarcinoma, Mucinous - mortality | Validation Studies as Topic | Fallopian Tube Neoplasms - mortality | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | bevacizumab | predictive | ICON7 | proteomics | serum | biomarkers
Journal Article
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 2, pp. 399 - 410
The role of endogenous androgens and sex hormone-binding globulin (SHBG) in ovarian carcinogenesis is poorly understood. Epithelial invasive ovarian cancer... 
histologic subtype | endogenous androgens | ovarian carcinoma | androstenedione | Cancer Research | Oncology | Medicine(all) | type II tumors | type I tumors | SERUM | PREMENOPAUSAL WOMEN | STEROID-HORMONES | SEX STEROIDS | REPRODUCIBILITY | HORMONE-RECEPTOR EXPRESSION | ONCOLOGY | ESTROGEN | CARCINOMAS | FREE TESTOSTERONE | POSTMENOPAUSAL WOMEN | Fallopian Tube Neoplasms - epidemiology | Prognosis | Prospective Studies | Follow-Up Studies | Peritoneal Neoplasms - epidemiology | Peritoneal Neoplasms - blood | Humans | Middle Aged | Neoplasms, Glandular and Epithelial - epidemiology | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - pathology | Case-Control Studies | Fallopian Tube Neoplasms - blood | Neoplasms, Glandular and Epithelial - blood | Neoplasm Grading | Androgens - blood | Aged, 80 and over | Adult | Female | Nutritional Status | Cystadenocarcinoma, Serous - epidemiology | Cystadenocarcinoma, Serous - blood | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Neoplasm Invasiveness | Risk Factors | Europe - epidemiology | Ovarian Neoplasms - blood | Sex Hormone-Binding Globulin - metabolism | Fallopian Tube Neoplasms - pathology | Ovarian Neoplasms - epidemiology | Carcinoma, Ovarian Epithelial | Aged | Neoplasm Staging | Androgens | Blood & organ donations | Health risk assessment | Ovarian cancer | Tumors | Index Medicus | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Cancer and Oncology | Klinisk medicin | Cancer och onkologi
Journal Article
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2010, Volume 119, Issue 3, pp. 444 - 450
Abstract Purpose To compare progression-free survival (PFS), overall survival (OS) and toxicities of thalidomide versus tamoxifen and to evaluate serum... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | CA-125 | Recurrence | Tamoxifen | Thalidomide | VEGF | Ovarian cancer | ANGIOGENESIS | EFFICACY | ESTROGEN-RECEPTOR | CONGENITAL ABNORMALITIES | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | THERAPY | GENE | ONCOLOGY | DISEASE | PATIENT SURVIVAL | PROGRESSION | Peritoneal Neoplasms - blood | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents, Hormonal - adverse effects | Fallopian Tube Neoplasms - blood | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - therapeutic use | Endpoint Determination | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Female | Angiogenesis Inhibitors - adverse effects | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Thalidomide - adverse effects | CA-125 Antigen - blood | Administration, Oral | Vascular Endothelial Growth Factor A - blood | Ovarian Neoplasms - blood | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Tamoxifen - therapeutic use | Aged | Tamoxifen - adverse effects | Thalidomide - therapeutic use | Bridged-Ring Compounds - administration & dosage | Chemotherapy | Carcinoma | Clinical trials | Product development | Vascular endothelial growth factor | Cancer | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 9, pp. 1638 - 1648
Abstract Background Vandetanib is an oral tyrosine kinase inhibitor of VEGFR-2/3, EGFR and RET, which has demonstrated clinical activity as a single agent and... 
Hematology, Oncology and Palliative Medicine | Chemotherapy | Vandetanib | Primary peritoneal cancer | Randomised phase II | Fallopian tube cancer | Epithelial cancer | Clinical trial | Taxanes | Ovarian cancer | PLACEBO | GYNECOLOGIC-ONCOLOGY-GROUP | TUMOR ANGIOGENESIS | RESISTANT OVARIAN | CELL LUNG-CANCER | TRIAL | THERAPY | ONCOLOGY | IN-VIVO | DOUBLE-BLIND | ENDOTHELIAL GROWTH-FACTOR | Peritoneal Neoplasms - blood | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Fallopian Tube Neoplasms - blood | Neoplasms, Glandular and Epithelial - blood | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Quinazolines - administration & dosage | Ovarian Neoplasms - drug therapy | Taxoids - adverse effects | Fallopian Tube Neoplasms - drug therapy | Piperidines - administration & dosage | Docetaxel | Ovarian Neoplasms - blood | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Piperidines - adverse effects | Neoplasms, Glandular and Epithelial - drug therapy | Quinazolines - adverse effects | Carcinoma, Ovarian Epithelial | Aged | Antimitotic agents | Medical research | Care and treatment | Relapse | Medicine, Experimental | Antineoplastic agents | Vascular endothelial growth factor | Diseases | Index Medicus
Journal Article
Journal Article
Journal Article